Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 4/20 | 0.79 |
| ▸ | DRD4 | P21917 | 4/20 | 0.79 |
| ▸ | DRD3 | P35462 | 4/20 | 0.79 |
| ▸ | LMNA | P02545 | 4/20 | 0.72 |
| ▸ | HTT | P42858 | 3/20 | 0.72 |
| ▸ | GAA | P10253 | 1/20 | 0.72 |
| ▸ | HTR6 | P50406 | 2/20 | 0.71 |
| ▸ | HTR7 | P34969 | 2/20 | 0.71 |
| ▸ | HTR1A | P08908 | 1/20 | 0.71 |
| ▸ | HTR2A | P28223 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | BCHE | P06276 | 1/20 | 0.66 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4772684 | 0.89 | KDM4E (0.69) | DRD2DRD4DRD3LMNAHTT | |
| SCHEMBL1787164 | 0.88 | DRD4 (1.00) | DRD2DRD4DRD3LMNAHTT | |
| SCHEMBL4775148 | 0.88 | DRD2 (0.62) | DRD2DRD4DRD3LMNAHTT | |
| SCHEMBL11820831 | 0.86 | HTR1A (0.79) | DRD2LMNAHTR6HTR7HTR1A | |
| SCHEMBL9367741 | 0.85 | HTR1A (0.74) | DRD2LMNAHTR6HTR7HTR1A | |
| SCHEMBL5198952 | 0.84 | DRD2 (0.63) | DRD2DRD4DRD3LMNAHTT | |
| SCHEMBL5198681 | 0.83 | HTR7 (1.00) | DRD2DRD4DRD3LMNAHTT | |
| SCHEMBL17482339 | 0.82 | BCHE (0.69) | DRD2DRD4DRD3LMNAHTT | |
| SCHEMBL5198132 | 0.81 | LMNA (0.72) | DRD2DRD4DRD3LMNAHTT | |
| SCHEMBL6589437 | 0.80 | HTR1A (0.71) | DRD2LMNAHTR6HTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0496692-A1 | 2-Methoxyphenylpiperazine derivatives | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (FAES) (ES) | 1992-07-29 | — | — | EP | claimed |
| US-9566284-B2 | Agents and methods for treating ischemic and other diseases | NONO INC. (CA) | 2017-02-14 | — | — | US | disclosed |
| US-9566284-B2 | Agents and methods for treating ischemic and other diseases | NONO INC. (CA) | 2017-02-14 | — | — | US | disclosed |
| US-9334256-B2 | Agents and methods for treating ischemic and other diseases | NONO INC. (CA) | 2016-05-10 | — | — | US | disclosed |
| US-20140235619-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO INC. (CA) | 2014-08-21 | — | — | US | disclosed |
| US-20140235619-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO INC. (CA) | 2014-08-21 | — | — | US | disclosed |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | NONO INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | NONO INC. (CA) | 2014-08-07 | — | — | US | disclosed |
| CN-101544592-B | Process for preparation of N-arylsulfonyl-3-substituted indoles | SUVEN LIFE SCIENCES LTD | 2013-08-21 | — | — | CN | disclosed |
| WO-2012174488-A2 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO, INC. (CA) | 2012-12-20 | — | — | WO | disclosed |
| US-20110251182-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO, INC. (CA) | 2011-10-13 | — | — | US | disclosed |
| US-20110251182-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | NONO, INC. (CA) | 2011-10-13 | — | — | US | disclosed |
| CN-1720225-B | N-arylsulfonyl-3-substituted indoles having 5-hydroxytryptamine receptor affinity, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LTD | 2011-05-18 | — | — | CN | disclosed |
| US-7875605-B2 | 1-Benzenesulfonyl-3-(4-methylpiperazin-1-ylmethyl)-5-nitro-1 H-indole; 1-[[5-Bromo-1-(2-Bromo-4-methoxybenzenesulfonyl)-indo1-3-yl]methyl][1,4]diazepane; useful for treating psychotic and neurodegenerative disorders e.g. schizophrenia, Alzheimer's disease, Parkinson's disease and Huntington's chorea | SUVEN LIFE SCIENCES LIMITED (IN) | 2011-01-25 | — | — | US | disclosed |
| CN-101544592-A | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them | SUVEN LIFE SCIENCES LTD (IN) | 2009-09-30 | — | — | CN | disclosed |
| EP-1581492-B1 | N-ARYLSULFONYL-3-SUBSTITUTED INDOLES HAVING SEROTONIN RECEPTOR AFFINITY, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2008-07-16 | — | — | EP | disclosed |
| US-20060223890-A1 | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2006-10-05 | — | — | US | disclosed |
| CN-1720225-A | N-arylsulfonyl-3-substituted indoles having 5-hydroxytryptamine receptor affinity, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LTD (IN) | 2006-01-11 | — | — | CN | disclosed |
| US-5142052-A | Cationic effect-driven carbinol/amine reaction | LABORATOIRES SYNTEX (FR) | 1992-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251182-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | TRPM7, TRPM8, TRPM6 | DRD2 4688/4885DRD4 4771/4885DRD3 4731/4885 |
| US-20060223890-A1 | N-arylsulfonyl-3-substituted indoles having serotonin receptor affinity, process for their preparation and pharmaceutical composition containing them | HTR3A, HTR3C, HTR2C | DRD2 89/4885DRD4 161/4885DRD3 68/4885 |
| US-20140235619-A1 | AGENTS AND METHODS FOR TREATING ISCHEMIC AND OTHER DISEASES | TRPM7, TRPM8, TRPM6 | DRD2 4688/4885DRD4 4771/4885DRD3 4731/4885 |
| US-20140221423-A1 | Agents And Methods For Treating Ischemic And Other Diseases | TRPM7, TRPM8, TRPM5 | DRD2 4587/4885DRD4 4703/4885DRD3 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.